Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates (Q39254744)

10 September 2017

title

Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates (English)

1 reference

10 September 2017

1 reference

Robert Chapman

3

0 references

Brendan L. Wilkinson

object named as

Brendan L Wilkinson

1

0 references

Vasso Apostolopoulos

object named as

Vasso Apostolopoulos

5

0 references

Sébastien Perrier

object named as

Sébastien Perrier

4

0 references

author name string

Stephanie Day

2

1 reference

10 September 2017

Richard J Payne

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

22 October 2012

1 reference

Chemistry—A European Journal

10 September 2017

published in

1 reference

10 September 2017

volume

18

1 reference

10 September 2017

issue

51

1 reference

10 September 2017

page(s)

16540-16548

1 reference

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Mucin-type O-glycosylation and its potential use in drug and vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Glycans in cancer and inflammation--potential for therapeutics and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Immunotherapy for cancer: synthetic carbohydrate-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Carbohydrate vaccines: developing sweet solutions to sticky situations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Carbohydrate vaccines as immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Synthetic Antitumor Vaccines from Tetanus Toxoid Conjugates of MUC1 Glycopeptides with the Thomsen–Friedenreich Antigen and a Fluorine‐Substituted Analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Robust immune responses elicited by a fully synthetic three-component vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Induction of carbohydrate-specific antibodies in HLA-DR transgenic mice by a synthetic glycopeptide: a potential anti cancer vaccine for human use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Synthesis and biological evaluation of a multiantigenic Tn/TF-containing glycopeptide mimic of the tumor-related MUC1 glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Lipopeptide structure determines TLR2 dependent cell activation level

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Synthesis of the glycopeptide O-beta-D-galactopyranosyl-(1 to 3)-O-(2-acetamido-2-desoxy-alpha-D-galactopyranosyl)-(1 to 3)-L-serine and -L-threonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Combining a polar resin and a pseudo-proline to optimize the solid-phase synthesis of a 'difficult sequence'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Peptide-based subunit nanovaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Polymer-peptide chimeras for the multivalent display of immunogenic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A self-assembling peptide acting as an immune adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Pathogen recognition and development of particulate vaccines: does size matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

A simple approach to characterizing block copolymer assemblies: graphene oxide supports for high contrast multi-technique imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Towards a comprehensive view of immunoglobulin class switching

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Polyacrylate Dendrimer Nanoparticles: A Self-Adjuvanting Vaccine Delivery System

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

Effect of O-glycosylation and tyrosinesulfation of leech-derived peptides on binding and inhibitory activity against thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCHEM.201202629

21 January 2018

Identifiers

DOI

10.1002/CHEM.201202629

1 reference

10 September 2017

1 reference